The Patent Finder

Geron Corporation

35 patents currently held · Updated Nov 16, 2026
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

7
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 27 to 28, 2027 · next Feb 27
  • 1 fee due Mar 15, 2027
    The maintenance fee for Rna Amidates and Thioamidates for Rnai (US 9,133,233) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
  • 1 fee due Apr 13, 2027
    The maintenance fee for Treatment of Carcinomas with a Combination of Egf-Pathway and Telomerase Inhibitors (US 9,155,753) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
  • 2 fees due Jun 1 to 3, 2027 · next Jun 1
  • 1 fee due Jul 5, 2027
    The maintenance fee for C-Myc Antisense Oligonucleotides and Methods for Using the Same to Treat Cell-Proliferative Disorders (US 9,228,189) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
  • 2 fees due Aug 2 to 18, 2027 · next Aug 2

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,998,938Cancer Treatment by Combined Inhibition of Proteasome and Telomerase Activities
In force
 · High confidence
In forceHigh confidence
US 7,989,428Combined Telomerase Inhibitor and Gemcitabine for the Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 9,133,233Rna Amidates and Thioamidates for Rnai
In force
 · High confidence
In forceHigh confidence
US 9,617,583Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
In force
 · High confidence
In forceHigh confidence
US 10,196,677Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
In force
 · High confidence
In forceHigh confidence
US 8,877,723Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
In force
 · High confidence
In forceHigh confidence
US 9,155,753Treatment of Carcinomas with a Combination of Egf-Pathway and Telomerase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,249,452Method of Detecting and Assaying Telomerase Activity of Telomerase Bound by Anti-Telomerase Antibodies
In force
 · High confidence
In forceHigh confidence
US 9,593,137Guanine Analogs as Telomerase Substrates and Telomere Length Affectors
In force
 · High confidence
In forceHigh confidence
US 10,035,814Guanine Analogs as Telomerase Substrates and Telomere Length Affectors
In force
 · High confidence
In forceHigh confidence
10 of 35 patents shown.
Pro members see all 35.
Pro members: see all 35 patents
Also on record, not counted in the 35: 15 patents in force now held by others · 46 lapsed for an unpaid fee · 152 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 14 abandoned · 24 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited